Tenet Healthcare Corporation
THC · New York Stock Exchange · USD
293,10USD
+2,83 (+0,97 %)Stand 11. Nov., 20:59
Kennzahlen
- Eröffnung
- 289,19
- Vortag
- 290,27
- Tagesspanne
- 282,94 – 293,42
- 52 Wochen
- 157,58 – 301,44
- Volumen
- 581.820
- Ø Volumen
- 937.631
- Börsenwert
- 23,33 Mrd. $
- KGV
- 8,4
- Gewinn je Aktie (TTM)
- 34,48
- Dividendenrendite
- 0,0 %
- Beta
- 1,2
- Nächste Zahlen
- 10. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 21,31 Mrd. | 20,67 Mrd. | 20,55 Mrd. | 19,17 Mrd. | 19,49 Mrd. |
| Herstellungskosten | 3,78 Mrd. | 12,46 Mrd. | 12,74 Mrd. | 12,13 Mrd. | 12,22 Mrd. |
| Bruttogewinn | 17,53 Mrd. | 8,21 Mrd. | 7,81 Mrd. | 7,05 Mrd. | 7,27 Mrd. |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 8,71 Mrd. | 8,8 Mrd. | 418 Mio. | 412 Mio. | 412 Mio. |
| Operatives Ergebnis | 3,44 Mrd. | 5,96 Mrd. | 2,51 Mrd. | 2,33 Mrd. | 2,87 Mrd. |
| EBITDA | 4,48 Mrd. | 6,89 Mrd. | 3,39 Mrd. | 3,08 Mrd. | 3,67 Mrd. |
| Nettogewinn | 1,41 Mrd. | 3,2 Mrd. | 611 Mio. | 411 Mio. | 914 Mio. |
| Gewinn je Aktie (verwässert) | 15,49 | 32,70 | 5,71 | 3,79 | 8,42 |
Umsatz nach Segment
Produkte · FY 2025
- Ambulatory Care5,17 Mrd. $50,22 %+14,07 %
- Hospital Operations5,13 Mrd. $49,78 %−9,18 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 8,4
- Kurs-Umsatz-Verhältnis
- 1,0
- Kurs-Buchwert-Verhältnis
- 4,3
- PEG
- 0,1
- Bruttomarge
- 29,4 %
- Operative Marge
- 19,8 %
- Nettomarge
- 12,7 %
- Verschuldungsgrad
- 2,4
- EV/EBITDA
- 5,7
- Eigenkapitalrendite
- 60,6 %
- Kapitalrendite (ROIC)
- 13,8 %
- Free-Cashflow-Rendite
- 14,3 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 82,3 % | 39,7 % | 38,0 % | 36,8 % | 37,3 % |
| Operative Marge | 16,1 % | 28,8 % | 12,2 % | 12,2 % | 14,7 % |
| Nettomarge | 6,6 % | 15,5 % | 3,0 % | 2,1 % | 4,7 % |
| KGV | 12,7 | 3,8 | 12,6 | 12,7 | 9,6 |
| Kurs-Umsatz-Verhältnis | 0,8 | 0,6 | 0,4 | 0,3 | 0,4 |
| Kurs-Buchwert-Verhältnis | 4,2 | 2,9 | 4,8 | 4,6 | 8,5 |
| Verschuldungsgrad | 3,1 | 3,4 | 9,3 | 13,2 | 15,2 |
| Liquidität 3. Grades | 1,8 | 1,8 | 1,5 | 1,3 | 1,4 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 28,2 Mrd. | 23,54 Mrd. | 21,45 Mrd. | 19,44 Mrd. | 22,01 Mrd. |
| EV/EBITDA | 6,3 | 3,4 | 6,3 | 6,3 | 6,0 |
| Eigenkapitalrendite | 33,3 % | 76,7 % | 38,0 % | 36,0 % | 88,9 % |
| Kapitalrendite (ROIC) | 11,5 % | 18,5 % | 8,6 % | 7,6 % | 9,9 % |
| Free-Cashflow-Rendite | 14,1 % | 9,1 % | 21,1 % | 6,2 % | 10,4 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +3,1 % | +0,6 % | +7,2 % | −1,6 % | +10,5 % |
| Bruttogewinn | +113,5 % | +5,2 % | +10,7 % | −3,0 % | +16,6 % |
| Operatives Ergebnis | −42,3 % | +137,3 % | +7,6 % | −18,7 % | +44,3 % |
| Nettogewinn | −56,0 % | +423,7 % | +48,7 % | −55,0 % | +129,1 % |
| Gewinn je Aktie | −52,6 % | +472,7 % | +50,7 % | −55,0 % | +124,5 % |
| Freier Cashflow | +126,7 % | −31,2 % | +405,6 % | −64,7 % | −68,3 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 26Kaufen
- 6Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
289,00
Durchschnitt · −1,40 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 22,3 Mrd. | 22,5 Mrd. | 23,47 Mrd. |
| Umsatz (Tief – Hoch) | 22,17 Mrd. – 22,58 Mrd. | 22,28 Mrd. – 23,08 Mrd. | 22,97 Mrd. – 24,42 Mrd. |
| Gewinn je Aktie (Ø) | 22,57 | 20,35 | 22,13 |
| Gewinn je Aktie (Tief – Hoch) | 20,97 – 23,59 | 18,05 – 23,38 | 19,10 – 25,53 |
| Analysten | 11 | 12 | 6 |
Letzte Änderungen
- Barclays4. Nov. 2026Overweight
- Keybanc3. Nov. 2026Overweight
- Truist Securities3. Nov. 2026Buy
- Wells Fargo2. Nov. 2026Overweight
- Leerink Partners2. Nov. 2026Outperform
- RBC Capital2. Nov. 2026Outperform
- Guggenheim30. Okt. 2026Buy
- Guggenheim16. Okt. 2026Buy
Quartalszahlen
Nächste Zahlen: 10. Feb. 2027| Okt. 2026 | Juli 2026 | Apr. 2026 | Feb. 2026 | Okt. 2025 | Juli 2025 | Apr. 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 4,68 | 4,26 | 4,17 | 4,07 | 3,34 | 2,87 | 3,12 | 2,95 |
| Gewinn je Aktie · Tatsächlich | 6,64 | 6,12 | 4,82 | 4,70 | 3,70 | 4,02 | 4,36 | 3,44 |
| Abweichung | +41,88 % | +43,66 % | +15,59 % | +15,48 % | +10,78 % | +40,07 % | +39,74 % | +16,61 % |
| Umsatz · Tatsächlich | 5,63 Mrd. | 5,63 Mrd. | 5,37 Mrd. | 5,53 Mrd. | 5,29 Mrd. | 5,27 Mrd. | 5,22 Mrd. | 5,07 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 13. März 2000 | 24. März 2000 | 0,01 |
| 16. Aug. 1993 | 10. Sept. 1993 | 0,12 |
| 17. Mai 1993 | 11. Juni 1993 | 0,12 |
| 12. Feb. 1993 | 12. März 1993 | 0,12 |
| 6. Nov. 1992 | 4. Dez. 1992 | 0,12 |
| 10. Aug. 1992 | 4. Sept. 1992 | 0,12 |
| 11. Mai 1992 | 5. Juni 1992 | 0,12 |
| 10. Feb. 1992 | 6. März 1992 | 0,12 |
| 8. Nov. 1991 | 6. Dez. 1991 | 0,12 |
| 12. Aug. 1991 | 6. Sept. 1991 | 0,23 |
| 13. Mai 1991 | 7. Juni 1991 | 0,20 |
| 11. Feb. 1991 | 8. März 1991 | 0,20 |
Aktiensplits
- 11. Okt. 20121:4
- 1. Juli 20023:2
- 16. Sept. 19912:1
- 27. Apr. 19835:4
- 30. Apr. 19812:1
- 5. Nov. 19803:2
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 93,13 %
- Investoren mit 13F-Meldung
- 720
Größte Investoren
- BLACKROCK, INC.10,47 %8,74 Mio.
- PRICE T ROWE ASSOCIATES INC /MD/9,53 %7,96 Mio.
- BOSTON PARTNERS5,31 %4,43 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC5,07 %4,24 Mio.
- FMR LLC4,78 %3,99 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC4,66 %3,89 Mio.
- STATE STREET CORP3,17 %2,75 Mio.
- GLENVIEW CAPITAL MANAGEMENT, LLC2,68 %2,24 Mio.
Insider-Geschäfte
- KERREY J ROBERT14. Sept. 2026 · directorVerkauf5483 Aktien · 263,04
- KERREY J ROBERT14. Sept. 2026 · directorVerkauf4025 Aktien · 264,10
- KERREY J ROBERT14. Sept. 2026 · directorVerkauf2502 Aktien · 264,62
- MARK RICHARD J10. Sept. 2026 · directorVerkauf10.000 Aktien · 263,42
- West Nadja2. Sept. 2026 · directorVerkauf1152 Aktien · 258,80
- Foo Lisa Y31. Aug. 2026 · officer: EVP, Chief Operating OfficerVerkauf24.000 Aktien · 266,32
- HANEY CECIL D28. Aug. 2026 · directorVerkauf150 Aktien
- HANEY CECIL D24. Aug. 2026 · directorVerkauf1300 Aktien · 278,03
Vergleichbare Unternehmen
4013.SRDr. Sulaiman Al Habib Medical Services Group Company212,90−0,84 %
ARDTArdent Health Inc.18,19+1,42 %
CONConcentra Group Holdings Parent, Inc.43,45+1,83 %
CYHCommunity Health Systems, Inc.2,30+5,99 %
FSNUYFresenius SE & Co. KGaA14,72−1,82 %
HCAHCA Healthcare, Inc.505,87+0,29 %
RDOR3.SARede D'Or São Luiz S.A.34,19+2,40 %
RMYHYRamsay Health Care Limited9,410,00 %
Über das Unternehmen
Tenet Healthcare Corporation operates as a broad-ranging provider of health solutions. The company organizes its operations across three main divisions: Hospital Operations and Other, Ambulatory Care, and Conifer. Within its network of acute care facilities, Tenet delivers a full spectrum of essential services. These include core hospital functions such as operating and recovery suites, radiology and respiratory therapy, clinical laboratories, and on-site pharmacies. The organization also provides high-acuity patient care through intensive, critical, and coronary care units. Specialized medical services cover areas like cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics, alongside various outpatient treatments, including physical therapy. Advanced surgical capabilities feature cardiothoracic, complex spinal, and neurosurgery, as well as neonatal intensive care. Tenet extends its offerings to ultra-specialized quaternary care, exemplified by heart and kidney transplant programs, and sophisticated procedures such as limb-salvaging vascular interventions, acute Level 1 trauma care, intravascular stroke treatment, minimally invasive cardiac valve replacements, advanced imaging, and telemedicine access. Beyond its hospital network, Tenet manages numerous other clinical sites. These encompass outpatient surgical centers, immediate care facilities, diagnostic imaging centers, dedicated surgical hospitals, off-campus emergency departments, and micro-hospitals. Through its Conifer segment, the company furnishes critical healthcare business process solutions. These administrative services, offered to hospitals, health systems, physician practices, employers, and other clients, include financial administration for patient accounts (revenue cycle management), support for patient communications and engagement, and outcome-focused care strategies. As of February 9, 2022, Tenet's operational footprint included 60 hospitals and roughly 550 additional medical facilities. This count of additional sites comprises surgical hospitals, ambulatory surgery centers, urgent care and imaging centers, and various other clinical locations. Tenet Healthcare Corporation was established in 1975 and maintains its principal office in Dallas, Texas.
Führung
- Saumya SutariaChairman & Chief Executive Officer
- Thomas W. ArnstEVice President, Chief Administrative Officer, Chief Risk Officer, General Counsel & Corporate Secretary
- Lisa Y. FooExecutive Vice President & Chief Operating Officer
- Sun K. ParkExecutive Vice President & Chief Financial Officer
- Paola ArbourExecutive Vice President & Chief Information Officer
- Clint HaileyChief Managed Care Officer & Senior Vice President
- CEO
- Saumya Sutaria
- Mitarbeitende
- 88.500
- Hauptsitz
- Dallas, TX, US
- Sektor
- Healthcare
- Branche
- Medical - Care Facilities
- Börsengang
- 17. März 1980
- Website
- tenethealth.com
Nachrichten
- Zacks Investment Research · 6. Nov., 10:46Here's Why Tenet Healthcare (THC) is a Strong Growth Stock
- 24/7 Wall Street · 5. Nov., 14:44Hospital Stocks Soared as Democrats Took Congress
- Barrons · 4. Nov., 13:16Healthcare Stocks Bounce on Midterm Results. A Bull Market Case Is Developing.
- Zacks Investment Research · 4. Nov., 10:01Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It
- MarketBeat · 30. Okt., 22:14Tenet Healthcare Q3 Earnings Call Highlights
- Zacks Investment Research · 30. Okt., 11:02THC Q3 Earnings Call Highlights Higher Outlook and Margin Gains
- Zacks Investment Research · 29. Okt., 16:15THC Q3 Earnings Beat on Hospital Strength, 2026 EPS View Raised
- Seeking Alpha · 29. Okt., 14:48Tenet Healthcare Corporation (THC) Q3 2026 Earnings Call Transcript
- Zacks Investment Research · 29. Okt., 12:31Tenet (THC) Reports Q3 Earnings: What Key Metrics Have to Say
- Zacks Investment Research · 29. Okt., 9:36Tenet Healthcare (THC) Surpasses Q3 Earnings and Revenue Estimates
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.